AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), in
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh